Dr Suresh S. Ramalingam presents data on a large randomised phase II study, GALAXY-1, during a press conference at the 2013 ASCO Annual Meeting.

The study found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line (salvage) therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma that progresses after initial therapy. If confirmed in an ongoing phase III trial, this would be the first treatment to improve patient outcomes in this setting in a decade.

Visit ecancerNews to read more